Screening Tool Artificial Intelligence-based for Predicting the Genetic Risk of BREAST Cancer
Recruiting now
Conditions studied: Breast Neoplasms
In brief
It is a retrospective observational study that will include female patients aged 18 years or older, who were treated between 2017 and 2024, in both public and private institutions, and identified as at high genetic risk by breast specialists and referred to a geneticist. The artificial intelligence-based tool to be used in this study is developed by the startup WeConecta, which will collect data via WhatsApp about the patients' family cancer history with the aim of predicting the genetic risk of developing breast cancer.
Key facts
- Study ID
- NCT07070128
- Run by
- AstraZeneca
- People needed
- 800
- Starts
- 2025-08-20
- Expected to finish
- 2026-08-11
- Last updated by the study team
- 2026-07-29
Who can join
Age: any. Sex: female. Healthy volunteers: not accepted.
You may qualify if…
- female patients,
- aged 18 years or older,
- identified as high genetic risk by breast surgeons,
- referred to a geneticist, and
- who agree to participate in the study.
You may not qualify if…
- male patients,
- absence of complete information in the medical records,
- patients unaware of their biological family history, and
- patients who do not agree to participate in the study.
Where it is running
- Research Site — Porto Alegre, Rio Grande do Sul, Brazil (enrolling)
- Research Site — Golania, Goiás, Brazil
- Research Site — Porto Alegre, Rio Grande do Sul, Brazil
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.